INTRODUCTION
============

Thinking, reading, writing, and throwing a baseball are all activities in which neural activity is coupled with local elevation in cerebral blood flow. This coupling is a hallmark of normal brain function and forms the basis of functional hyperemia ([@R1], [@R2]). Functional hyperemia plays critical roles in functional brain imaging ([@R3], [@R4]), and defects in functional hyperemia are believed to contribute to synaptic loss and cognitive decline in multiple neurodegenerative diseases including Alzheimer's disease ([@R5]--[@R8]). The question of what drives functional hyperemia, however, is still unclear despite decades of research ([@R1], [@R9]--[@R13]). Most recently, it has emerged that cerebral functional hyperemia is initiated in capillaries rather than upstream in arterioles in the brain, thus challenging the existing dogma that the capillary bed is a passive conduit for upstream vasodilation ([@R14], [@R15]). Several initial publications have suggested that pericytes control capillary blood flow, but later studies could not confirm contractility of pericytes ([@R16]--[@R19]). In particular, the third-order branches of capillary pericytes do not express smooth muscle actin and should therefore be unable to constrict ([@R15], [@R16]). Our group has shown recently that the initial (transient) dip in tissue oxygen tension (*P*O~2~) after hindlimb stimulation drives brain capillary hyperemia, and furthermore, that *P*O~2~ can itself, independent of the neurovascular unit, control red blood cell (RBC) deformability, thus modulating RBC flow through capillaries ([@R15]). Hence, RBCs are active players in capillary hyperemia and promptly increase O~2~ delivery in response to activity-induced local changes in *P*O~2~. RBC-mediated capillary hyperemia provides a simple yet robust mechanism for swift and precise local increases in capillary flow in response to the ever-changing patterns of neural activity within the central nervous system. However, the underlying mechanisms of how RBCs control their deformability and capillary velocity in response to changes of local *P*O~2~ remain elusive.

We hypothesize that deoxygenated hemoglobin (deoxyHb) and band 3 interactions on RBC membrane disrupt the band 3--ankyrin linkage during RBC deoxygenation ([Fig. 1A](#F1){ref-type="fig"}), resulting in membrane detachment and increased RBC deformability and, consequently, an elevated capillary velocity. *P*O~2~ has been shown to be able to regulate multiple RBC activities including glucose metabolism ([@R20], [@R21]), cation transport ([@R22]), adenosine triphosphate release ([@R23], [@R24]), and cytoskeletal organization ([@R24]--[@R27]). The reversible binding of deoxyHb with band 3, in particular, has been postulated to be critical in many of these processes. This is because the cytoplasmic domain of band 3 contains the only known Hb binding site on the RBC membrane and Hb--band 3 interactions are strongly O~2~ dependent ([@R28]--[@R30]). Here, to address the hypothesized roles of Hb--band 3 interactions in *P*O~2~-mediated capillary hyperemia, we combined ex vivo microfluidics and in vivo two-photon microscopy and meticulously examined RBC deformability and capillary velocity as a function of *P*O~2~ using RBCs from human, wild-type (WT) mice, and transgenic mice that have modified RBC deoxyHb--band 3 interactions. Moreover, the dynamics of *P*O~2~-mediated RBC capillary velocity and the quantitative relation between RBC deformability and capillary velocity were unveiled to shed light on the governing physical principles of capillary hyperemia. Last, we would like to emphasize that because RBCs circulate in the circulatory system throughout the entire body, the demonstrated roles of *P*O~2~ in the regulation of RBC capillary velocity are not only limited to the brain but also apply to any organs with high oxygen consumption.

![DeoxyHb--band 3 interactions regulate *P*O~2~-mediated RBC capillary velocity.\
(**A**) Schematics of the hypothesized Hb--band 3 interactions during deoxygenation. The binding of deoxyHb to band 3 during RBC deoxygenation weakens the band 3--ankyrin interactions, resulting in more deformable RBCs. (**B**) Schematics of transgenic mouse RBCs (mRBCs) with modified deoxyHb--band 3 interactions. (**C**) Microfluidic setup for ex vivo analysis of *P*O~2~-mediated RBC velocity in capillary. The microfluidic device was submerged in a sulfite sink with 0, 0.01, 0.1, or 1 M sodium sulfite to control the *P*O~2~ inside the microfluidic channel. A high-speed camera was used to record RBC motion in the capillary. (**D**) Time-lapse images showed that mRBCs flow faster at reduced *P*O~2~. Scale bar, 5 μm. (**E**) mRBC velocity in capillary as a function of *P*O~2~. The velocity of mRBC-WT and mRBC-subst 1-35 changes linearly with *P*O~2~ \[mRBC-WT: *n* = 146, RBC velocity (mm/s) = −0.132 × *P*O~2~ (mmHg) + 26.455, *R*^2^ = 0.979; mRBC-subst 1-35: *n* = 149, RBC velocity (mm/s) = −0.151 × *P*O~2~ (mmHg) + 28.913, *R*^2^ = 0.995\]. (**F**) The velocity of mRBC-WT is significantly lower than that of mRBC-subst 1-35 at each *P*O~2~ level. \*\*\**P* \< 0.001, *t* test. (**G**) The velocity of mRBC-del 1-11 and mRBC-del 12-23 is not sensitive to surrounding *P*O~2~ changes and remains relatively constant at 22.88 ± 1.59 mm/s (*n* = 157) and 20.23 ± 1.63 mm/s (*n* = 115), respectively. \*\*\**P* \< 0.001, *t* test. (**H**) A schematic of the experimental setup for ex vivo analysis of RBC deformability as a function of *P*O~2~. The deformability of RBCs was characterized by the elongation index *D*~l~/*D*~w~, where *D*~l~ and *D*~w~ were, respectively, the length and thickness of an RBC flowing through the constriction. (**I**) The elongation index (*D*~l~/*D*~w~) of mRBC-WT and mRBC-subst 1-35 increased linearly as the decrease of *P*O~2~ \[mRBC-WT: *n* = 209, *D*~l~/*D*~w~ = −0.0228 × *P*O~2~ (mmHg) + 2.7548, *R*^2^ = 0.998; mRBC-subst 1-35: *n* = 195, *D*~l~/*D*~w~ = −0.0137 × *P*O~2~ (mmHg) + 2.6545, *R*^2^ = 0.994\]. (**J**) The elongation index of mRBC-del 1-11 and mRBC-del 12-23 was not sensitive to *P*O~2~ changes and remains relatively constant at 2.41 ± 0.31 (*n* = 195) and 1.94 ± 0.23 (*n* = 194), respectively. \*\*\**P* \< 0.001, *t* test. Error bars are shown as SE.](aaw4466-F1){#F1}

RESULTS
=======

DeoxyHb--band 3 interactions regulates *P*O~2~-mediated RBC capillary velocity
------------------------------------------------------------------------------

To explore the roles of deoxyHb--band 3 interactions in *P*O~2~-mediated RBC capillary velocity, we examined ex vivo RBC velocity in a microfluidic capillary using RBCs from three transgenic mice that had modified deoxyHb--band 3 interactions ([Fig. 1B](#F1){ref-type="fig"}) ([@R24]). The first strain of mouse had RBCs where the NH~2~-terminal residues 1 to 45 on the cytoplasmic domain of band 3 were replaced by the homologous sequence (residues 1 to 35) of human band 3 \[transgenic mouse RBC (mRBC)--subst 1-35\] ([@R27]). mRBC-subst 1-35 thus had the "humanized" band 3 and was used together with RBCs from WT mice (mRBC-WT) as control. RBCs from the second strain of mouse had the same humanized band 3 except that the deoxyHb--band 3 binding site, residues 12 to 23, was deleted (mRBC-del 12-23). As a result, deoxyHb--band 3 interactions in mRBC-del 12-23 were substantially weakened. RBCs from the third strain also had the same humanized band 3, but a homologous sequence (1-MEELQDDYEDM-11) adjacent to residues 12 to 23 of band 3 was removed (mRBC-del 1-11). Because residues 1 to 11 are known to inhibit band 3 interactions with deoxyHb, removal of residues 1 to 11 enchances deoxyHb--band 3 interactions ([@R27]). We used RBCs from these three strains of mouse together with mRBC-WT to examine RBC velocity as a function of *P*O~2~ in microfluidics ([Fig. 1C](#F1){ref-type="fig"}). In particular, we dispersed RBCs into a phosphate-buffered saline (PBS) buffer that was purged by N~2~ overnight. We then injected the RBC suspension at a constant pressure (1.1 × 10^4^ Pa) into a polydimethylsiloxane (PDMS) microfluidic device containing a constriction capillary (*w*~c~ = 3 μm; *h* = 4.5 μm). We immersed the entire microfluidic device in an aqueous sink containing sodium sulfite (an O~2~ scavenger) and controlled the *P*O~2~ inside the microfluidic channel by varying the sulfite concentration (fig. S1A). We recorded the motion of RBCs as a function of *P*O~2~ in the constriction using a high-speed camera ([Fig. 1D](#F1){ref-type="fig"}). Consistent with previous findings in human RBCs (hRBCs) ([@R15]), the velocity of mRBC-WT and mRBC-subst 1-35 increased linearly with the decrease in *P*O~2~ ([Fig. 1E](#F1){ref-type="fig"}). The sensitivity of RBC velocity to *P*O~2~ changes (slope of the fitting curve) was not significantly different between mRBC-WT and mRBC-subst 1-35 (fig. S1B). The velocity of mRBC-subst 1-35, however, was significantly higher than that of mRBC-WT at each *P*O~2~ level ([Fig. 1F](#F1){ref-type="fig"}). Notably, when RBCs with enhanced (mRBC-del 1-11) or weakened (mRBC-del 12-23) deoxyHb--band 3 interactions were used, we completely abolished the dependence of RBC velocity on *P*O~2~ ([Fig. 1E](#F1){ref-type="fig"}). In addition, the average velocity of mRBC-del 12-23 was significantly lower than that of mRBC-del 1-11 ([Fig. 1G](#F1){ref-type="fig"}). These results demonstrate that modification of deoxyHb--band 3 interactions affects the sensitivity of RBC velocity to *P*O~2~ changes and reduced band 3--deoxyHb interactions lead to decreased RBC capillary velocity.

Because rheological properties of RBCs relate tightly to RBC velocity in microvessels, we next examined whether deoxyHb--band 3 interactions also regulated RBC deformability. [Figure 1H](#F1){ref-type="fig"} showed the microfluidic setup where a relatively wide constriction (*w*~c~ = 10 μm; *h* = 7.4 μm) was used to measure shear-induced elongation of RBCs. *P*O~2~ in the constriction was controlled by the sulfite sink (fig. S1C). We characterized the shear-induced RBC elongation using the elongation index, *D*~l~/*D*~w~, where *D*~l~ and *D*~w~ were, respectively, the length and thickness of an RBC flowing through the constriction. As shown in [Fig. 1I](#F1){ref-type="fig"}, elongation index of mRBC-WT and mRBC-subst 1-35 increased linearly with the decrease in *P*O~2~, indicating increased RBC deformability at reduced *P*O~2~. When RBCs with modified deoxyHb--band 3 interactions were used (mRBC-del 12-23 and mRBC-del 1-11), the elongation index of these RBCs was not dependent on *P*O~2~, and the average elongation index of mRBC-del 12-23 was significantly smaller than that of mRBC-del 1-11 ([Fig. 1J](#F1){ref-type="fig"}). These sets of data show that deoxyHb--band 3 interactions regulate RBC deformability during RBC deoxygenation and that the change of RBC deformability correlates tightly with RBC capillary velocity.

Transgenic mice with modified deoxyHb--band 3 interactions exhibit *P*O~2~-independent capillary hyperemia in vivo
------------------------------------------------------------------------------------------------------------------

Although ex vivo microfluidic experiments demonstrated that the dependence of RBC capillary velocity on *P*O~2~ could be manipulated by altering the RBC deoxyHb--band 3 interactions, whether RBC deoxyHb--band 3 interactions affect in vivo capillary hyperemia remained unknown. To address this question, we used a laser scanning two-photon microscope to measure in vivo RBC capillary velocity as a function of tissue *P*O~2~ in the cerebral cortex of WT mice (mRBC-WT) and transgenic mice (mRBC-subst 1-35, mRBC-del 1-11, and mRBC-del 12-23). Under the guidance of two-photon imaging, we microinjected sodium sulfite solution to the hindlimb cortex of a mouse brain to control local tissue *P*O~2~ near capillaries ([Fig. 2A](#F2){ref-type="fig"}). Microinjection of sulfite triggered a rapid decrease in local tissue *P*O~2~, and these *P*O~2~ dips increased as the sulfite concentration was elevated ([Fig. 2B](#F2){ref-type="fig"}). Note that the biphasic pattern of *P*O~2~ response to sulfite injection, e.g., an initial transient dip followed by a delayed long-lasting overshoot, was similar to previously observed activity-dependent *P*O~2~ responses ([@R15]). We then measured RBC velocity in capillaries as a function of local tissue *P*O~2~ using two-photon line scan. A typical line-scan image acquired with longitudinal line scan before and after sulfite injection in mRBC-WT is shown in [Fig. 2C](#F2){ref-type="fig"}, where *x* represents the scanning distance and *t* is time. Each RBC in the line-scan image appeared as a black stripe, and the slope of the stripe represented RBC velocity, *v*, which increased upon sulfite injection. In mRBC-WT and mRBC-subst 1-35 mice, the peak velocity and the increase of peak velocity relative to the baseline velocity upon 1 M sulfite injection were significantly higher than that upon 0.01 M sulfite injection ([Fig. 2, D and E](#F2){ref-type="fig"}, and fig. S2), suggesting that in vivo RBC capillary velocity was regulated by local *P*O~2~ changes in control mice. In contrast, the peak velocity and the increase of peak velocity after sulfite injection in mRBC-del 1-11 mice ([Fig. 2F](#F2){ref-type="fig"}) and mRBC-del 12-33 mice ([Fig. 2G](#F2){ref-type="fig"}) did not change with the increase in sulfite, suggesting that local *P*O~2~ changes failed to regulate RBC capillary velocity when RBC deoxyHb--band 3 interactions were modified. Note that although the increase of capillary velocity did not change with sulfite concentration, capillary velocity did increase upon sulfite injection in mRBC-del 1-11 and mRBC-del 12-33 mice. This is likely due to the increase of blood flow upstream in arterioles after sulfite injection ([@R15]), supported by the observed long onset time of capillary velocity increase in mRBC-del 12-33 ([Fig. 2H](#F2){ref-type="fig"}). These results are consistent with our ex vivo findings and show that in vivo capillary hyperemia is controlled by RBC deoxyHb--band 3 interactions.

![Transgenic mice with modified deoxyHb--band 3 interactions exhibit *P*O~2~-independent capillary hyperemia in vivo.\
(**A**) Experimental setup for in vivo assessing cerebral capillary hyperemia and tissue *P*O~2~ upon locally applied O~2~ scavenger (sodium sulfite, 0.01 and 1 M) in a mouse cerebral cortex. Through a cranial window, sodium sulfite was microinjected by a micropipette inserted 100 to 150 μm below the pial surface and placed \<50 μm from a capillary. Puffing micropipette and O~2~ sensor microelectrode were placed in close proximity (\<50 μm). RBC velocity in capillary was imaged using two-photon laser scanning microscopy. Scale bar, 30 μm. (**B**) Local changes of *P*O~2~ were dose dependent on the concentration of microinjected sulfite. The transient reduction in *P*O~2~ was followed by a *P*O~2~ overshoot. *n* = 12 and 4 mice. \**P* \< 0.05, *t* test. (**C**) Typical images of the two-photon line scan of a capillary before and after the microinjection of sulfite. Black stripes represented RBCs. RBC velocity was obtained by calculating the slopes of the stripes. (**D**) Time-course plot of RBC capillary velocity increases after microinjection of sulfite for WT mice (mRBC-WT; *n* = 217 capillaries and 10 mice) and transgenic mice with (**E**) humanized band 3 (mRBC-subst 1-35; *n* = 153 capillaries and 8 mice), (**F**) enhanced deoxyHb--band 3 interactions (mRBC-del 1-11; *n* = 243 capillaries and 10 mice), and (**G**) weakened deoxyHb--band 3 interactions (mRBC-del 12-23; *n* = 243 capillaries and 10 mice). \**P* \< 0.05, \*\**P* \< 0.01, *t* test. (**H**) The onset time of increase of RBC capillary velocity after sulfite puffing in WT and transgenic mice. \**P* \< 0.05, \*\*\**P* \< 0.001, *t* test. Error bars are shown as SE. NS, not significant.](aaw4466-F2){#F2}

Biochemical modulation of deoxyHb--band 3 interactions in WT RBCs regulates *P*O~2~-mediated RBC capillary velocity
-------------------------------------------------------------------------------------------------------------------

To further evaluate the roles of deoxyHb--band 3 interactions in *P*O~2~-mediated RBC capillary velocity, we varied deoxyHb--band 3 and band 3--cytoskeletal interactions in mRBC-WT and hRBCs via phosphoenolpyruvate (PEP), sodium phosphate (Pi), or pervanadate treatment ([Fig. 3A](#F3){ref-type="fig"}) ([@R28], [@R31]--[@R33]). PEP treatment increased intracellular concentration of 2,3-diphosphoglyceric acid (2,3-DPG) in RBCs, whereas Pi treatment decreased 2,3-DPG concentration (fig. S3A). Because 2,3-DPG binds preferably to deoxyHb ([@R34]), increase or decrease of 2,3-DPG will change the amount of deoxyHb available to band 3. This change of deoxyHb is thus expected to alter the magnitude and kinetics of deoxyHb--band 3 interactions ([@R28]) and consequently affects *P*O~2~-mediated RBC capillary velocity. The sensitivity of RBC velocity to *P*O~2~ changes (slope of the fitting curve) was significantly reduced when RBCs were treated with PEP and Pi ([Fig. 3, B and C](#F3){ref-type="fig"}, and fig. S3B). At each *P*O~2~ level, the velocity of RBCs treated with PEP was significantly lower than that of RBCs treated with Pi (fig. S3, C and D). In addition, when RBCs were treated with pervanadate that directly triggered tyrosine phosphorylation of band 3 and induced the dissociation of band 3 from its ankyrin linkage to the spectrin-actin skeleton ([@R32]), the dependence of RBC velocity on *P*O~2~ was completely abolished ([Fig. 3, B and C](#F3){ref-type="fig"}). The velocity of RBCs treated with pervanadate was also significantly higher than that of RBCs treated with PEP at different *P*O~2~ levels (fig. S3, C and D). These observations demonstrate that intracellular 2,3-DPG concentration and band 3 phosphorylation regulate *P*O~2~-mediated RBC capillary velocity in WT RBCs, likely via the modulation of deoxyHb--band 3 and band 3--cytoskeletal interactions, respectively. In addition, the sensitivity of RBC deformation to *P*O~2~ changes was significantly reduced after PEP and Pi treatments and diminished after pervanadate treatment ([Fig. 3, D and E](#F3){ref-type="fig"}, and fig. S3E). The magnitude of elongation index at each *P*O~2~ level was lower for RBCs treated with PEP compared to RBCs treated with Pi and pervanadate (fig. S3, F and G). These results show that 2,3-DPG concentration and band 3 phosphorylation control RBC deformation. Moreover, the similar trend between RBC deformation and capillary velocity as a function of *P*O~2~ after PEP, Pi, and pervanadate treatments highlights again the tight correlation between RBC deformability and its capillary velocity.

![Biochemical modulation of deoxyHb--band 3 interactions regulates *P*O~2~-mediated RBC capillary velocity.\
(**A**) Left: DeoxyHb--band 3 interactions are manipulated by increasing (via PEP treatment) or decreasing (via Pi treatment) intracellular concentration of 2,3-DPG. Right: Tyrosine phosphorylation of band 3 (via pervanadate treatment) promotes dissociation of band 3 from the spectrin-actin skeleton. (**B**) The velocity of hRBC-WT, hRBC-Pi, and hRBC-PEP decreased linearly with the increase of *P*O~2~ \[hRBC-WT: *n* = 71, RBC velocity (mm/s) = −0.451× *P*O~2~ (mmHg) + 82.074, *R*^2^ = 0.999; hRBC-Pi: *n* = 174, RBC velocity (mm/s) = −0.068× *P*O~2~ (mmHg) + 79.332, *R*^2^ = 0.947; hRBC-PEP: *n* = 167, RBC velocity (mm/s) = −0.065× *P*O~2~ (mmHg) + 74.198, *R*^2^ = 0.906\]. The velocity of hRBC-pervanadate was not sensitive to *P*O~2~ changes and remained constant at 79.56 ± 0.28 mm/s (*n* = 198). Compared to hRBC-WT, the sensitivity of RBC velocity to *P*O~2~ changes (as indicated by the slope) was reduced in hRBC-Pi and hRBC-PEP. \*\*\**P* \< 0.001, *t* test. (**C**) The velocity of mRBC-WT, mRBC-Pi, and mRBC-PEP decreased linearly with the increase of *P*O~2~ \[mRBC-WT: *n* = 146, RBC velocity (mm/s) = −0.132 × *P*O~2~ (mmHg) + 26.455, *R*^2^ = 0.981; mRBC-Pi: *n* = 159, RBC velocity (mm/s) = −0.11 × *P*O~2~ (mmHg) + 28.296, *R*^2^ = 0.938; mRBC-PEP: *n* = 146, RBC velocity (mm/s) = −0.071 × *P*O~2~ (mmHg) + 22.557, *R*^2^ = 0.885\]. Compared to mRBC-WT, the sensitivity of RBC capillary velocity to *P*O~2~ changes was reduced after Pi and PEP treatments. \**P* \< 0.05, \*\*\**P* \< 0.001, *t* test. (**D**) The elongation index of hRBC-WT, hRBC-Pi, and hRBC-PEP decreased linearly with the increase of *P*O~2~ \[hRBC-WT: *n* = 239, *D*~l~/*D*~w~ = −0.0236 × *P*O~2~ (mmHg) + 4.0001, *R*^2^ = 0.934; hRBC-Pi: *n* = 132, *D*~l~/*D*~w~ = −0.0143 × *P*O~2~ (mmHg) + 4.142, *R*^2^ = 0.947; hRBC-PEP: *n* = 144, *D*~l~/*D*~w~ = −0.0102 × *P*O~2~ (mmHg) + 3.6698, *R*^2^ = 0.997\]. hRBC-pervanadate deformation was not sensitive to *P*O~2~ changes and remained constant at 4.08 ± 0.02 mm/s (*n* = 216). \**P* \< 0.05, \*\**P* \< 0.01, *t* test. (**E**) The elongation index of mRBC-WT, mRBC-Pi, and mRBC-PEP decreased linearly with the increase of *P*O~2~ \[mRBC-WT: *n* = 207, *D*~l~/*D*~w~ = −0.0228 × *P*O~2~ (mmHg) + 2.7548, *R*^2^ = 0.993; mRBC-Pi: *n* = 125, *D*~l~/*D*~w~ = −0.005 × *P*O~2~ (mmHg) + 2.8088, *R*^2^ = 0.988; mRBC-PEP: *n* = 120, *D*~l~/*D*~w~ = −0.0107 × *P*O~2~ (mmHg) + 2.4383, *R*^2^ = 0.989\]. mRBC-pervanadate deformation was not sensitive to *P*O~2~ changes and remained relatively constant at 2.44 ± 0.03 mm/s (*n* = 216). \*\*\**P* \< 0.001, *t* test. Error bars are shown as SE.](aaw4466-F3){#F3}

Dynamics of *P*O~2~-mediated RBC capillary velocity
---------------------------------------------------

Although the results from both ex vivo and in vivo experiments have shown that deoxyHb--band 3 and band 3--cytoskeletal interactions contribute to *P*O~2~-mediated RBC capillary velocity, several critical questions still remain. For example, if the band 3--ankyrin linkage is ruptured during RBC deoxygenation, then the RBC membrane will be released from its underlying cytoskeletal network. If so, is there any evidence showing RBC membrane detachment during deoxygenation? Does the duration of deoxygenation play a role in such a process and in *P*O~2~-mediated RBC capillary velocity? How can one quantitatively relate RBC capillary velocity to its deformability?

To answer these questions, we first examined the change of RBC membrane-cytoskeletal interactions during deoxygenation by measuring RBC tank-treading frequency as a function of *P*O~2~. Tank-treading motion of an RBC refers to the rotation of the RBC membrane around the cell body, which usually occurs in a shear flow. The velocity of this motion is mainly determined by the applied shear rate, viscosity of the suspending medium, and the membrane-cytoskeletal interactions. Thus, RBCs with disrupted membrane-cytoskeletal interactions are expected to have an increased tank-treading velocity, given that the shear rate and medium viscosity are constant. [Figure 4A](#F4){ref-type="fig"} shows the microfluidic setup where a microfluidic channel with a constriction (*w*~c~ = 20 μm; *h* = 38 μm) was used to induce RBC tank-treading motion in flow. hRBCs attached with microspheres (1 μm, polystyrene) were injected to the microfluidic channel, and the tank-treading frequency \[*f* (s^−1^)\], which is the inverse of the orbital period (the time for the microbead moving along with the RBC)membrane to complete one revolution), was measured using a high-speed camera. In addition, we varied the length of the channel before constriction (600, 4200, and 12,000 μm) to examine whether the exposure time of reduced *P*O~2~, *t*~total~, affected RBC tank-treading motion. In these sets of experiments, *t*~total~ was controlled at 18 ± 4, 192 ± 30, and 377 ± 11 ms. We calibrated *P*O~2~ inside the channel as described previously (fig. S4A). The results showed that the normalized tank-treading frequency, *f* (s^−1^)/*f* (s^−1^)~34mmHg~, where *f* (s^−1^)~34mmHg~, is the tank-treading frequency measured at *P*O~2~ = 34 mmHg, increased linearly with the decrease in *P*O~2~ when *t*~total~ was 192 ± 30 and 377 ± 11 ms and was independent of *P*O~2~ changes when *t*~total~ was 18 ± 4 ms ([Fig. 4B](#F4){ref-type="fig"}). The sensitivity of the tank-treading frequency to *P*O~2~ changes was also increased with the increase in *t*~total~ and medium viscosity ([Fig. 4C](#F4){ref-type="fig"} and fig. S4B). RBC tank-treading frequency increased with the increase in viscosity of the RBC suspension ([@R35]), particularly at low *P*O~2~ levels (fig. S4C). Collectively, the facts that RBC tank-treading frequency increased at reduced *P*O~2~ and the sensitivity of tank-treading frequency to *P*O~2~ increased with *t*~total~ support evidently that RBC membrane is detached during deoxygenation and the duration of reduced *P*O~2~ plays a regulatory role.

![Dynamics of *P*O~2~-mediated RBC capillary velocity.\
(**A**) Schematics of experimental setup for ex vivo analysis of RBC tank-treading frequency, *f* (s^−1^), at reduced *P*O~2~. Human RBCs with microbeads (1 μm, polystyrene) attached on the cell membrane (inset images) were injected into a microfluidic channel with a constriction. *f* (s^−1^) was calculated on the basis of the orbital periods (the time for the microbead moving along with the membrane for one revolution) of the microbead. *t*~total~ is the total exposure time of reduced *P*O~2~ that RBC experienced before constriction and controlled by varying the length of the channel before constriction. Scale bar, 5 μm. (**B**) Normalized *f* (s^−1^) as a function of *P*O~2~ at different *t*~total~. Dextran was added to increase the viscosity of RBC suspension. *f* (s^−1^) was normalized by dividing *f* (s^−1^) at *P*O~2~ = 34 mmHg. *f* (s^−1^)/*f* (s^−1^)~34mmHg~ did not change with *P*O~2~ when *t*~total~ = 18 ± 4 ms but increased linearly with the decrease of *P*O~2~ when *t*~total~ = 192 ± 30 and 377 ± 11 ms. The sensitivity to *P*O~2~ changes increased as the increase of viscosity. At *t*~total~ = 192 ± 30 ms, η = 1.36 mPa·s: *n* = 80, *f* (s^−1^)/*f* (s^−1^)~34mmHg~ = −0.0043 × *P*O~2~ (mmHg) + 1.1326, *R*^2^ = 0.839; η = 2.61 mPa·s: *n* = 116, *f* (s^−1^)/*f* (s^−1^)~34mmHg~ = −0.0062 × *P*O~2~ (mmHg) + 1.2036, *R*^2^ = 0.959; η = 4.66 mPa·s: *n* = 120, *f* (s^−1^)/*f* (s^−1^)~34mmHg~ = −0.0115 × *P*O~2~ (mmHg) + 1.3509, *R*^2^ = 0.874. At *t*~total~ = 377 ± 11 ms, η = 1.36 mPa·s: *n* = 129, *f* (s^−1^)/*f* (s^−1^) ~34mmHg~ = −0.0072 × *P*O~2~ (mmHg) + 1.2253, *R*^2^ = 0.894; η = 2.61 mPa·s: *n* = 160, *f* (s^−1^)/*f* (s^−1^)~34mmHg~ = −0.0117 × *P*O~2~ (mmHg) + 1.3677, *R*^2^ = 0.920; η = 4.66 mPa·s: *n* = 120, *f* (s^−1^)/*f* (s^−1^)~34mmHg~ = −0.0141 × *P*O~2~ (mmHg) + 1.4461, *R*^2^ = 0.924. (**C**) Effect of *t*~total~ on the sensitivity of *f* (s^−1^)/*f* (s^−1^) ~34mmHg~ to *P*O~2~ changes. \*\**P* \< 0.01 and \*\*\**P* \< 0.001, *t* test. (**D**) Normalized RBC capillary velocity *V*~0mmHg~/*V*~34mmHg~ (where *V*~0mmHg~ and *V*~34mmHg~ are RBC velocity at *P*O~2~ = 0 mmHg and *P*O~2~ = 34 mmHg, respectively) as a function of *t*~total~. Critical *t*~total~ beyond which RBC velocity did not change with *t*~total~ was identified as 462 ± 71, 913.4 ± 63, and 955.1 ± 57 ms for hRBC-WT, mRBC-subst 1-35, and mRBC-WT, respectively. (**E**) Schematics of the relation between *P*O~2~, RBC deformability, and RBC capillary velocity. RBCs become more deformable at reduced *P*O~2~ and thus have a smaller cell width (*r*~0~) when flowing in a capillary with a diameter of 2*R*~0~. As a result, the gap distance between the surface of RBC and the capillary wall (*R*~0~ − *r*~0~) increases, leading to reduced hydrodynamic drag and thus increased RBC velocity. (**F**) Experimental measured changes of RBC width *r*~0~ and RBC velocity *v* as a function of *P*O~2~. *r*~0\ 34mmHg~ and *v*~34mmHg~ were *r*~0~ and *v*, respectively, at *P*O~2~ = 34 mmHg. Error bars are shown as SE.](aaw4466-F4){#F4}

The observed effect of *t*~total~ on RBC tank-treading frequency led us to hypothesize that *t*~total~ might also regulate RBC capillary velocity. To test the hypothesis, we measured RBC velocity in a series of microfluidic capillaries under controlled *t*~total~ (fig. S4D). The results shown in [Fig. 4D](#F4){ref-type="fig"} demonstrated that the normalized RBC velocity, *V*~0mmHg~/*V*~34mmHg~, where *V*~0mmHg~ and *V*~34mmHg~ were the RBC velocity at *P*O~2~ = 0 mmHg and 34 mmHg, respectively, was independent of *t*~total~ for transgenic mice with modified band 3--deoxyHb interactions (mRBC-del 1-11 and mRBC-del 12-23). In contrast, the normalized RBC velocity of hRBC-WT, mRBC-subst 1-35, and mRBC-WT increased with the increase in *t*~total~ and reached a maximum velocity at a threshold *t*~total~ of 462 ± 71, 913.4 ± 63, and 955.1 ± 57 ms, respectively. Notably, the critical *t*~total~ of mRBC-subst 1-35 is shorter than that of mRBC-WT, consistent with the shortest onset time in mRBC-subst 1-35 observed in vivo ([Fig. 2H](#F2){ref-type="fig"}). These results thus show that the duration of reduced *P*O~2~ regulates RBC capillary velocity and that there is a critical *P*O~2~ exposure time beyond which RBC capillary velocity reaches a plateau and does not change with further increase in *P*O~2~ exposure time.

Last, we evaluate the correlation between RBC capillary velocity and RBC deformability by analyzing the changes of RBC width *r*~0~ in capillary as a function of *P*O~2~ ([Fig. 4E](#F4){ref-type="fig"}). As shown in [Fig. 4F](#F4){ref-type="fig"}, the normalized cell width, *r*~0~/*r*~0\ 34mmHg~, where *r*~0\ 34mmHg~ is the cell width measured at *P*O~2~ = 34 mmHg, decreased with the decrease in *P*O~2~, whereas RBC capillary velocity increased concurrently, implying that RBC capillary velocity increases as *r*~0~ decreases. According to the classical Bretherton scaling for a long bubble flowing in a microchannel, the surface tension of the gas bubble σ relates to its radius in channel *r*~0\ bubble~ by Ca^2/3^ = (μ*v*/σ)^2/3^ ∝ (*R*~0~ − *r*~0\ bubble~)/*R*~0~, where *R*~0~ is the radius of the microchannel, Ca = μ*v*/σ is the capillary number, μ is the viscosity, and *v* is the velocity. Applying the Bretherton scaling to RBCs flowing in a capillary and replacing *r*~0\ bubble~ and σ with RBC width *r*~0~ and RBC membrane tension *E* (assuming *E* is uniform on RBC), respectively, we obtain (μ*v*/*E*)^2/3^ ∝ (*R*~0~ − *r*~0~)/*R*~0~. A small *E*, e.g., a more deformable RBC, thus corresponds to a large gap distance (*R*~0~ − *r*~0~) and, consequently, a small *r*~0~, given that *R*~0~ is constant. As a result, RBCs with increased deformability will have a small *r*~0~ when flowing in a capillary, and a small *r*~0~ correlates to a high RBC capillary velocity, as experimentally observed in [Fig. 4F](#F4){ref-type="fig"}. To further quantitatively assess the relation between *r*~0~ and RBC capillary velocity, we calculated the shear stress acting on RBCs in capillary using lubrication approximation and showed that the nondimensional RBC capillary velocity is a function of *r*~0~ (fig. S4E). Therefore, RBC capillary velocity relates to RBC deformability through the change of cell width *r*~0~ inside the capillary. With a decrease in *P*O~2~, RBCs become more deformable due to the deoxyHb--band 3 and band 3--cytoskeletal interactions and have a reduced cell width *r*~0~. This decrease in *r*~0~ leads to an increase in the gap distance between the channel wall and RBC membrane and reduces hydrodynamic drag, which in turn increases RBC capillary velocity.

DISCUSSION
==========

Recent studies have revealed that functional hyperemia is initiated in capillaries ([@R14], [@R15]) and that RBCs themselves can act as oxygen-sensing regulators to control capillary RBC velocity in response to local *P*O~2~ changes ([@R15]). However, the underlying mechanisms of how *P*O~2~ could modulate RBC velocity in capillaries are unknown. Experimental findings presented here implicate that deoxyHb--band 3 interactions in RBCs are the molecular switch that responds to local *P*O~2~ changes and controls RBC deformability and consequently RBC capillary velocity. Evidently, we showed that (i) while ex vivo capillary velocity and deformation of mRBC-WT and mRBC-subst 1-35 exhibited a linear relation with local *P*O~2~ changes, RBCs from transgenic mice that had enhanced or weakened deoxyHb--band 3 interactions showed capillary velocity and deformation independent of *P*O~2~. RBCs with enhanced deoxyHb--band 3 interactions showed higher capillary velocity and deformability compared to RBCs that had weakened deoxyHb--band 3 interactions. (ii) Consistent with ex vivo results, in vivo cerebral capillary hyperemia in WT mice (mRBC-WT) and mRBC-subst 1-35 but not that with enhanced or weakened deoxyHb--band 3 interactions was dependent on local *P*O~2~ changes. (iii) Direct dissociation of band 3--ankyrin interactions in both mRBC-WT and hRBCs via pervanadate treatment resulted in *P*O~2~-independent RBC capillary velocity and deformation. Changing the amount of deoxyHb available to band 3 interactions by manipulating the intracellular concentration of 2,3-DPG via Pi or PEP treatment reduced the sensitivity of RBC capillary velocity, and deformation to *P*O~2~ changes. RBCs with increased 2,3-DPG (via Pi treatment) showed higher capillary velocity and deformability compared to RBCs that had decreased 2,3-DPG (via PEP treatment). (iv) RBC membrane tank-treading frequency increased linearly with the decrease in *P*O~2~. The magnitude and sensitivity of tank-treading frequency to *P*O~2~ changes increased with the increase in *P*O~2~ exposure time and medium viscosity. (v) RBC capillary velocity depended on the duration of reduced *P*O~2~ until a threshold exposure time, beyond which RBC velocity remained maximum and did not change with the exposure time anymore. Collectively, these sets of data indicate that RBC deoxyHb--band 3 and band 3--cytoskeletal interactions regulate *P*O~2~-mediated RBC capillary velocity and that both the magnitude and duration of reduced *P*O~2~ play critical roles.

The observation of the independence of RBC capillary velocity and deformation on *P*O~2~ changes in mRBC-del 12-23 and RBCs treated with pervanadate has led us to conclude that RBCs could not either sense *P*O~2~ changes when the deoxyHb binding site on band 3 was deleted or react to *P*O~2~ changes when band 3--ankyrin interactions were disrupted. However, the reason why RBCs with enhanced deoxyHb--band 3 interactions (mRBC-del 1-11) did not respond to *P*O~2~ changes is less obvious. Among other possible reasons, we speculate that the modified deoxyHb--band 3 binding kinetics in mRBC-del 1-11 and the relatively low *P*O~2~ level in the present study play a role. It is known that the average copies of Hb and band 3 per RBC is approximately 270,000,000 and 1,200,000, respectively ([@R36]). As a result, less than 0.5% Hb is needed to bind band 3 during deoxygenation. Deoxygenation of such a small amount of Hb requires almost negligible decrease of *P*O~2~ ([@R37]). Under the current experimental conditions where *P*O~2~ = 34 mmHg, it is likely that all the Hb that is available to band 3 was already deoxygenated. Because the inhibitory residues 1 to 11 on band 3 were deleted in mRBC-del 1-11, deoxyHb--band 3 association in mRBC-del 1-11 was stronger and faster compared to that in WT RBCs ([@R27]). As a result, as soon as Hb is deoxygenated and available to band 3, it will bind band 3 readily. Therefore, further decrease of *P*O~2~ from 34 to 0 mmHg will not affect the established deoxyHb--band 3 interactions and consequently cannot regulate RBC capillary velocity and deformation. The deoxyHb--band 3 interactions in WT RBCs are reversible, and the kinetic binding process depends on the concentration of available deoxyHb. As a result, the deformability and capillary velocity of WT RBCs are *P*O~2~ dependent. Furthermore, despite the fact that the velocity and deformation index of mRBC-del 1-11 and mRBC-del 12-23 are *P*O~2~ independent, the fact that mRBC-del 1-11 has a relatively high velocity and deformation index at *P*O~2~ = 34 mmHg ([Fig. 1, E and I](#F1){ref-type="fig"}) compared to that of mRBC-WT and mRBC-del 12-23 at the same *P*O~2~ further confirms our hypothesis.

The effect of the duration of reduced *P*O~2~ (*t*~total~) on RBC capillary velocity, together with the critical *t*~total~ observed in [Fig. 4D](#F4){ref-type="fig"}, highlights several important kinetic processes. First, there is a *P*O~2~ equilibrium process when RBC suspension is injected into the microfluidic channel that has a reduced *P*O~2~. The time scale of this process, *t*~diff~, can be calculated on the basis of the dimensions of the channel before constriction (*w* = 50 μm; *h* = 4.5 μm) and the O~2~ diffusion constant in water \[*D*~diff~ = 2.1 × 10^−9^ m^2^/s ([@R37])\], *t*~diff~ = *wh*/4*D*~diff~, and is approximately 27 ms. This fast *P*O~2~ equilibrium process is evidenced experimentally by the constant fluorescence intensity of an oxygen-sensitive dye flowing through the channel (fig. S4F). Second, after the *P*O~2~ equilibrium is established between the channel and RBC suspension, RBCs will experience the reduced *P*O~2~ in the medium and deoxygenation of RBCs occurs. For an RBC exposed to a zero *P*O~2~ at the cell boundary, the approximate time to achieve 50% desaturation, *t*~deoxy~, is about 30 to 50 ms ([@R38], [@R39]), although a longer time of 100 to 150 ms has also been observed ([@R37], [@R40]). In our case, the time required to deoxygenate 0.5% Hb necessary for band 3 interaction is expected to be much shorter than the reported *t*~deoxy~. Third, during RBC deoxygenation, deoxyHb binds band 3, and band 3--ankyrin dissociation starts to occur. The kinetics of deoxyHb--band 3 binding is fast \[the on-rate *k*~on~ and binding constant *K*~A~ are on the order of 10^6^/M s ([@R41]) and 10^6^/M ([@R26], [@R42]), respectively\], whereas the band 3--ankyrin dissociation is very slow \[the off-rate *k*~off~ and dissociation constant *K*~d~ are on the order of 10^−3^/s ([@R43]) and 10^−8^ M ([@R44], [@R45]), respectively\]. Thus, if the observed critical *t*~total~ represents these three kinetic processes, then band 3--ankyrin dissociation will be the rate-limiting step and likely accounts for the critical *t*~total~. As a result, band 3--ankyrin dissociation may be more important to the physiologic process, while the deoxyHb--band 3 interactions serve to maintain that dissociated state. Meanwhile, note that although the kinetics of deoxyHb--band 3 interactions is fast, it may also affect the kinetics of *P*O~2~-mediated RBC capillary velocity among different species. This is because the high-affinity ankyrin binding sites on band 3 are conserved among different species ([@R29]), but Hb--band 3 interactions are species specific and hRBCs have a higher binding affinity than mRBCs ([@R26], [@R46], [@R47]). Evidently, we observed in the present study that hRBCs have the shortest critical *t*~total~, followed by mRBC-subst 1-35 and mRBC-WT. In addition, mRBC-subst 1-35 has the shorter in vivo onset time of capillary hyperemia than WT mouse. Regardless of different kinetic processes between species, the fact that the critical *t*~total~ from either hRBCs or mRBC-WT is shorter than the in vivo RBC capillary transit time ([@R48]--[@R50]) suggests that RBCs can adjust their properties to local *P*O~2~ changes before exiting the capillary and thus facilitate O~2~ delivery and extraction.

Last, RBC volume might change during RBC deoxygenation and may contribute to *P*O~2~-mediated RBC capillary velocity. Several lines of evidence have suggested that deoxyHb--band 3 interactions trigger conformational changes of band 3 ([@R51]) and regulate RBC ion flux including RBC volume regulatory transporters ([@R52]--[@R54]). In addition, Piezo1, the mechanosensing ion channel on RBCs, is likely to be activated during capillary transit ([@R55]) and controls RBC volume ([@R56]). Whether and how RBC volume contributes *P*O~2~-mediated RBC capillary velocity are of interest for further studies, the present results nevertheless demonstrate that deoxyHb--band 3 and band 3--ankyrin interactions play critical roles in *P*O~2~-mediated RBC capillary velocity and contribute to cerebral functional hyperemia. These findings not only advance our understanding of the mechanisms of functional hyperemia in the brain but also provide universal principles of RBC-based blood flow regulation, and thus open up new opportunities to study neurodegenerative disease such as vascular dementia, where RBCs may contribute to the dysfunctions of blood flow regulation and, consequently, the observed neurodegenerative conditions.

MATERIALS AND METHODS
=====================

Animals and surgical preparation
--------------------------------

Three strains of transgenic mice (mRBC-subst 1-35, mRBC-del 1-11, and mRBC-del 12-23) were provided by D. Bodine from the National Institutes of Health. WT mice (mRBC-WT, C57BL/6J) were purchased from the Jackson Laboratory. Anesthesia was induced in experimental animals with 2.0% isoflurane in oxygen and maintained at 1.5 to 2.0% during surgical preparation. The depth of anesthesia was monitored by toe pinch and whisker movement. Body temperature was maintained by a water-perfused thermal pad (Gaymar T/Pump) set at 37°C. A custom-made metal plate was glued to the skull, and a 1.5- to 2.5-mm-diameter cranial window was made over the hindlimb cortex for imaging (stereotaxic coordinates, 0.5 to 3 mm lateral and −1.5 to +1 mm anterior of bregma). Agarose (1.1% in artificial cerebrospinal fluid at 37°C) was applied, and a glass coverslip was sealed to the metal plate. All experimental procedures were approved by the University Committee on Animal Resources at the University of Rochester, and effort was taken to minimize the number of animals used. This research was approved by the institutional review boards at the Rochester Institute of Technology and the University of Rochester School of Medicine.

RBC preparation and treatment
-----------------------------

Whole blood was extracted from mice or healthy human donors and prepared on the day of use. RBCs were separated from plasma by centrifuging 1 ml of whole blood at 300*g* at 20°C for 1.5 min. The supernatant was removed by aspiration. The packed RBCs were resuspended and washed three times in PBS buffer. The RBCs were then diluted with a PBS solution (3%, v/v). Note that for all mRBCs, PBS buffer was prepared as follows: 152 mM NaCl, 2.7 mM KCl, 8.1 mM Na~2~HPO~4~, 1.47 KH~2~PO~4~, and 10 mM glucose (pH 7.4) (osmolality, 340 mOsm/kg). For hRBCs, PBS buffer was used as purchased from Thermo Fisher Scientific (pH 7.2) (osmolality, 280 to 320 mOsm/kg; catalog no. 20012027). PEP (phosphoenolpyruvate) and P~i~ (sodium phosphate) solutions were prepared in PBS as follows: 50 mM PEP, 28.8 mM Mannitol, 50 mM glucose, 20 mM NaCl, and 1 mM adenine for PEP solution; and 50 mM P~i~, 28.8 mM Mannitol, 50 mM glucose, 20 mM NaCl, and 1 mM adenine for P~i~ solution. pH of the solutions was adjusted to 6.0. Packed RBCs were suspended in either PEP or P~i~ solution, incubated for 1 hour at 37°C, and then washed twice with PBS. To determine the concentration of 2,3-DPG in RBCs, ultraviolet testing was conducted following the manufacturing protocol of Sigma Kit (catalog no. 10148334001, Sigma-Aldrich). In pervanadate treatment, packed RBCs were suspended in PBS with 0.5 mM sodium orthovanadate and 150 mM H~2~O~2~. After incubation at 37°C for 30 min, RBCs were washed three times using PBS and resuspended in a fresh PBS with glucose for 180 min to obtain 100% phosphorylation of band 3 and ankyrin.

Microfluidic device and RBC imaging
-----------------------------------

Microfluidic devices were fabricated with PDMS using standard soft photolithography techniques. The microfluidic device was connected via a short polyethylene (PE 20) tube to an RBC reservoir where a constant pressure (1.1 × 10^4^ Pa) was applied using a gas regulator (DPG1001B, OMEGA) with a precision of 689 Pa. To control *P*O~2~ inside the channel, the entire microfluidic device was immersed in a customized glass chamber filled with an aqueous solution containing 0, 0.01, 0.1, or 1.0 M sodium sulfite (Sigma-Aldrich), and the *P*O~2~ inside was equilibrated with the surrounding environment for 20 min before experiments. Although in vivo *P*O~2~ in capillaries varies in a wide range (i.e., \~5 to 95 mmHg), it tends to stay at the lower end of that range for most cases. Thus, a *P*O~2~ between 0 to 34 mmHg was chosen for the ex vivo microfluidic studies. For each experiment, RBCs from at least three mice or human individuals were used, and one to two microfluidic devices per mouse or human sample were used.

### PO~2~ calibration in microfluidics

To colorimetrically quantify the *P*O~2~ in the microfluidic channel, 25 μM tris(2,2′-bipyridyl)dichlororuthenium(II) hexahydrate (an O~2~ indicator; Sigma-Aldrich) was prepared in N~2~-bubbled or air-saturated deionized water and injected into the microfluidic device at a constant pressure (1.1 × 10^4^ Pa). The change in fluorescence intensity of the O~2~ indicator flowing through the microfluidic device was measured using a RatioMaster system (Photon Technology International) and converted to a *P*O~2~ value using the Stern-Volmer equation, *I*~0~/*I* = 1 + *P*O~2~ × *K*~q~, in which *I*~0~ is the maximum of the fluorescence intensity and *K*~q~ is the quenching constant. To calculate *I*~0~ and *K*~q~, we used *P*O~2~ of 34 and 174 mmHg, respectively, in N~2~-bubbled dye solution (after bubbling for 16 hours) and air-saturated dye solution, which was measured and calibrated using a World Precision Instruments dissolved O~2~ meter and a Bayer Rapidlab 248 blood gas analyzer. These values of *I*~0~ and *K*~q~ were then used to calculate *P*O~2~ in microfluidic channels.

### RBC velocity and deformability measurement

To measure mRBC velocity, we injected mRBCs into a microfluidic device with a constriction of *w*~c~ = 3 μm and *h* = 4.5 μm at a constant pressure of 1.1 × 10^4^ Pa. The movements of mRBCs in the constriction were recorded using a high-speed video camera (Phantom Miro M120; 1900 frames/s) mounted on an inverted microscope (Leica DMI6000B). The recorded videos were analyzed using Phantom Camera Control software and ImageJ, and mRBC velocity was calculated assuming a steady flow condition. To determine the deformability of mRBCs, we used a microfluidic device with a constriction of *w*~c~ = 10 μm and *h* = 7.4 μm. The deformation of mRBCs flowing through the constriction was recorded using the high-speed camera and characterized by the change of elongation index *D*~l~/*D*~w~, where *D*~l~ and *D*~w~ are the length and thickness of mRBC, respectively. To examine human RBC velocity and deformation as a function of *P*O~2~, we used the same approach as described above expect that a microfluidic device with a constriction of *w*~c~ = 5 μm and *h* = 7 μm and *w*~c~ = 20 μm and *h* = 30 μm was used, respectively, for the hRBC velocity and deformation measurement. To study the effect of total exposure time of reduced *P*O~2~ on RBC velocity, we used microfluidic devices with different lengths of channel before the constriction (100, 500, 1000, 1500, 3000, 5000, 7000, and 9000 μm) to control the total exposure time. In this case, the *P*O~2~ was controlled at 0 and 34 mmHg.

### RBC tank-treading frequency measurement

A microfluidic channel containing a constriction (*w*~c~ = 20 μm; *h* = 38 μm) was used to measure tank-treading frequency of hRBCs. The microfluidic device was immersed in a sulfite sink with different concentrations of sodium sulfite (0, 0.01, 0.1, and 1 M). The length of the channel before constriction was varied from 600, 4200, and 12000 μm to obtain a total exposure time of 18 ± 4, 192 ± 30, and 377 ± 11 ms, respectively. hRBC suspension (1 ml) in PBS (1.5%, v/v) was mixed with 10 μl of polystyrene microspheres \[0.5% (w/v) in PBS; Polybead, Polysciences Inc.\] and injected into the microfluidic channel. Dextran (*Leuconostoc* spp., relative molecular mass of 450,000 to 650,000; Sigma-Aldrich) was added to increase the viscosity of RBC suspension from 1.36 and 2.61 mPa·s to 4.66 mPa·s, as measured using a rheometer (Discovery HR-2 Hybrid Rheometer, TA Instruments). The rotation of the microbead on RBCs was recorded using a high-speed camera, and the tank-treading frequency was calculated as 1/the time for the microbead moving along with the membrane for one revolution. Note that to maintain a relatively constant velocity when the viscosity of RBC suspension was changed, the inject pressure was changed from 3.45 × 10^3^ to 8.96 × 10^3^, accordingly.

In vivo two-photon imaging
--------------------------

Two-photon imaging was performed using a Thorlabs two-photon setup attached to a Mai Tai HP Ti:Sapphire laser (Spectra-Physics). A 20× objective (0.9 numerical apperture; Olympus) was used. Intravascular fluorescein isothiocyanate--dextran (FITC-dextran; 2.5% in saline) was injected to the tail of the mouse and excited at 820 nm. To prepare the sulfite puffing solution, 0.01 or 1 M sodium sulfite was dissolved in 10 mM Hepes (with a drop of HCl to adjust pH to 7.3) containing 100 μM Alexa Fluor 594 and loaded into a glass micropipette with a tip diameter of 2 to 3 μm. The puffing micropipette was then carefully loaded into a capillary bed in the cerebral cortex, and the sulfite solution was puffed at 10 psi (\~20 ms) controlled by a Picospritzer III. Capillary RBC velocity was captured with line scans (scan rate, \~1 kHz) placed along the length of the capillary. RBC velocities (Δ*x*/Δ*t*, mm/s) were calculated from parallel-to-flow line-scan images using the contrast between FITC-dextran--labeled plasma and unlabeled RBCs, using a modified version of the LS-PIV algorithm in MATLAB.

### Local tissue PO~2~ measurement

Local tissue O~2~ tension was recorded with a calibrated modified Clark-type polarographic O~2~ microelectrode (OX-10, Unisense A/S, Aarhus, Denmark) inserted in close proximity to the puffing pipette (\~50 μm). The signal was amplified and analog-to-digital converted by a high-impedance picoammeter (OXY-Meter, Unisense A/S). Data were recorded in pCLAMP 9.0 and analyzed using Clampfit 10.4 and MATLAB.

### Parameter estimation

A zero-phase running average filter (window size, \~1 s) was used to smooth raw velocity data after outliers (raw data points of \>3 SDs from mean of trace) were removed. Onset of the evoked response was estimated by fitting a line to the slope between 20 and 80% to the peak of the response and calculating the time of the line's *x* intercept. Five to 10 s immediately before puffing stimulation was considered baseline, and responses occurring within 20 s after the start of stimulation were analyzed.
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Fig. S1. Calibration of oxygen level in microfluidic channels.

Fig. S2. Baseline RBC velocity in WT mice and transgenic mice before sulfite puffing.

Fig. S3. RBC 2,3-DPG and capillary velocity changes upon PEP and Pi treatments.

Fig. S4. Effect of medium viscosity on *P*O~2~-regulated RBC tank-treading frequency and the calculation of RBC capillary velocity as a function of RBC size.
